Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
It's fantastic! Cheap dildos in Sex Shop LoveToyLand.com!
Popular Articles

Health Canada Informs Pregnant And Breastfeeding Women Not To Take Vitamin Maxum Matragen And/or Maxum Multi Vite Supplements
Health Canada is advising expectant mothers and breastfeeding women not to take the vitamin-mineral supplements Maxum Matragen or Maxum Multi-Vite by Seroyal International Inc. Maxum Multi-Vite has been approved as a vitamin-mineral supplement for only the general public but lacks the required cautionary statement on the label regarding pregnant and/or breast feeding women. The product Maxum Matragen is being promoted by the company as a prenatal supplement; however, neither product has been authorized for sale by Health Canada for use by women who are pregnant or breastfeeding.
drugs without prescription
Interson Launches The SeeMore™ USB Ultrasound Imaging Probe
Interson announces the launch of the SeeMore USB Ultrasound Imaging probe. Inexpensive and portable, SeeMore probes plug directly into the USB port of a laptop, netbook, or desktop computer. General purpose and specialty probes are available for a wide range of clinical applications including: abdominal, OB/GYN, bladder scanning, emergency, vascular access, small parts, musculo-skeletal, nerve blocks, endocavity (prostate, transvaginal) and more, and range in frequency from 3.5 MHz to 24 MHz.
News of the day
Xanodyne Receives Approval From The U.S. Food And Drug Administration For ZIPSOR(TM) (diclofenac Potassium) Liquid Filled Capsules
Xanodyne Pharmaceuticals, Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Zipsor (diclofenac potassium) Liquid Filled Capsules, a new treatment option indicated for relief of mild to moderate acute pain in adults (18 years of age or older).
Medical Devices

Advanced Prostate Cancer - New Review On PROSTVAC(TM) Published By Key Investigators From NCI

A just published Review in the publication "Expert Opinion on Investigational Drugs", Volume 18, Issue 7 2009, confirms the previous published information on PROSTVAC(TM). This is the most comprehensive and updated Review on PROSTVAC(TM) so far. Quote from the article: "Preliminary clinical trials have indicated negligible toxicity, and Phase II trials have suggested a survival benefit after treatment with PROSTVAC(TM), especially in patients with indolent disease characteristics." Anders Hedegaard, President & CEO of Bavarian Nordic said: "We are very pleased that the scientific experts once again confirm their positive view on PROSTVAC(TM) and the potential use of the vaccine in earlier stages of the disease. We are looking forward to publish more data at a later stage." Background information: PROSTVAC(TM) is a therapeutic vaccine moving into late stage clinical development that has the potential to extend the lives of people with advanced prostate cancer. Administered subcutaneously, it induces a specific, targeted immune response that attacks prostate cancer cells. Conventional chemotherapy currently used to treat prostate cancer has limited survival rates and is often associated with numerous side effects. In contrast, PROSTVAC(TM) has the potential to extend survival with improved quality of life. PROSTVAC is being developed in collaboration with the National Cancer Institute under a Cooperative Research and Development Agreement with Bavarian Nordic"s U.S.-based subsidiary, BN ImmunoTherapeutics. In clinical trials to date PROSTVAC(TM) and related PSA containing poxviral vaccines have been investigated in more than 500 patients for 10 years. Bavarian Nordic


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009